Review




Structured Review

ReWalk Robotics Inc powered exoskeleton rewalktm
Powered Exoskeleton Rewalktm, supplied by ReWalk Robotics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/powered exoskeleton rewalktm/product/ReWalk Robotics Inc
Average 90 stars, based on 1 article reviews
powered exoskeleton rewalktm - by Bioz Stars, 2026-05
90/100 stars

Images



Similar Products

90
Argo Medical Technologies Ltd wearable powered exoskeleton rewalktm
Wearable Powered Exoskeleton Rewalktm, supplied by Argo Medical Technologies Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wearable powered exoskeleton rewalktm/product/Argo Medical Technologies Ltd
Average 90 stars, based on 1 article reviews
wearable powered exoskeleton rewalktm - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ReWalk Robotics Inc powered exoskeleton rewalktm
Powered Exoskeleton Rewalktm, supplied by ReWalk Robotics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/powered exoskeleton rewalktm/product/ReWalk Robotics Inc
Average 90 stars, based on 1 article reviews
powered exoskeleton rewalktm - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ReWalk Robotics Inc rewalktm powered exoskeleton
MEDLINE search strategy
Rewalktm Powered Exoskeleton, supplied by ReWalk Robotics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rewalktm powered exoskeleton/product/ReWalk Robotics Inc
Average 90 stars, based on 1 article reviews
rewalktm powered exoskeleton - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


MEDLINE search strategy

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: MEDLINE search strategy

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Powered  exoskeleton  training protocols

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Powered exoskeleton training protocols

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Ability to ambulate using a powered exoskeleton without physical assistance. Notes: Data represent the proportion of subjects who were able to ambulate using an exoskeleton without physical assistance at the end of the training period. Fixed effects estimates: 76.2% (95% CI: 66.7%–84.1%); random effects estimates: 76.2% (95% CI: 58.6%–90.1%); I 2 =73%, P <0.001. Abbreviation: CI, confidence interval.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Ability to ambulate using a powered exoskeleton without physical assistance. Notes: Data represent the proportion of subjects who were able to ambulate using an exoskeleton without physical assistance at the end of the training period. Fixed effects estimates: 76.2% (95% CI: 66.7%–84.1%); random effects estimates: 76.2% (95% CI: 58.6%–90.1%); I 2 =73%, P <0.001. Abbreviation: CI, confidence interval.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Outcomes of randomized controlled trial comparing powered exoskeleton, reciprocating gait orthosis, and hip-knee-ankle-foot orthosis. Notes: A is PCI, B is 6-min walk distance, and C is walking velocity. *Exoskeleton outcomes superior to RGO and HKAFO for walking velocity (both P <0.001), 6-minute walk distance ( P =0.03 vs RGO; P <0.01 vs HKAFO), and PCI (both P <0.001). Abbreviations: HKAFO, hip-knee-ankle-foot orthosis; PCI, physiological cost index; RGO, reciprocating gait orthosis.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Outcomes of randomized controlled trial comparing powered exoskeleton, reciprocating gait orthosis, and hip-knee-ankle-foot orthosis. Notes: A is PCI, B is 6-min walk distance, and C is walking velocity. *Exoskeleton outcomes superior to RGO and HKAFO for walking velocity (both P <0.001), 6-minute walk distance ( P =0.03 vs RGO; P <0.01 vs HKAFO), and PCI (both P <0.001). Abbreviations: HKAFO, hip-knee-ankle-foot orthosis; PCI, physiological cost index; RGO, reciprocating gait orthosis.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Six-minute walk test results with a powered exoskeleton. Notes: Data represent the number of meters walked with exoskeleton at the end of the training period. Fixed effects estimates: 99 m (95% CI: 92–106 m); random effects estimates: 98 m (95% CI: 80–117 m); I 2 =85%, P <0.001. Abbreviation: CI, confidence interval.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Six-minute walk test results with a powered exoskeleton. Notes: Data represent the number of meters walked with exoskeleton at the end of the training period. Fixed effects estimates: 99 m (95% CI: 92–106 m); random effects estimates: 98 m (95% CI: 80–117 m); I 2 =85%, P <0.001. Abbreviation: CI, confidence interval.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Metabolic equivalents with powered exoskeleton walking. Notes: Data represent the number of metabolic equivalents (METs) required for exoskeleton walking at the end of the training period. METs were calculated as 1 MET per 2.7 mL O 2 /kg based on the estimated or measured maximal aerobic capacity values, unless otherwise specified. Fixed effects estimates: 3.9 METs (95% CI: 3.8, 4.0 METs); random effects estimates: 3.3 METs (95% CI: 2.2, 4.4 METs); I 2 =98%, P <0.001. Abbreviation: CI, confidence interval.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Metabolic equivalents with powered exoskeleton walking. Notes: Data represent the number of metabolic equivalents (METs) required for exoskeleton walking at the end of the training period. METs were calculated as 1 MET per 2.7 mL O 2 /kg based on the estimated or measured maximal aerobic capacity values, unless otherwise specified. Fixed effects estimates: 3.9 METs (95% CI: 3.8, 4.0 METs); random effects estimates: 3.3 METs (95% CI: 2.2, 4.4 METs); I 2 =98%, P <0.001. Abbreviation: CI, confidence interval.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Rating of perceived exertion with powered exoskeleton walking. Notes: Data represent subjective rating of perceived exertion (RPE; Borg 6–20 scale) required for exoskeleton walking at the end of the training period. Fixed and random effects estimates: 10.1 (95% CI: 9.0, 11.3); I 2 =0%, P =0.97. Abbreviations: CI, confidence interval; RPE, rating of perceived exertion.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Rating of perceived exertion with powered exoskeleton walking. Notes: Data represent subjective rating of perceived exertion (RPE; Borg 6–20 scale) required for exoskeleton walking at the end of the training period. Fixed and random effects estimates: 10.1 (95% CI: 9.0, 11.3); I 2 =0%, P =0.97. Abbreviations: CI, confidence interval; RPE, rating of perceived exertion.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Spasticity decreases with powered exoskeleton training. Notes: Data represent the proportion of subjects who reported decreases in spasticity with exoskeleton training. Fixed effects estimates: 36.7% (95% CI: 21.9%, 53.6%); random effects estimates: 37.7% (95% CI: 18.5%, 59.2%); I 2 =46%, P =0.12. Abbreviation: CI, confidence interval.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Spasticity decreases with powered exoskeleton training. Notes: Data represent the proportion of subjects who reported decreases in spasticity with exoskeleton training. Fixed effects estimates: 36.7% (95% CI: 21.9%, 53.6%); random effects estimates: 37.7% (95% CI: 18.5%, 59.2%); I 2 =46%, P =0.12. Abbreviation: CI, confidence interval.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Improvements in bowel movement regularity with powered exoskeleton training. Notes: Data represent the proportion of subjects who reported improvements in bowel movement regularity with exoskeleton training. Fixed effects estimates: 57.7% (95% CI: 37.3%, 76.3%); random effects estimates: 60.9% (95% CI: 19.5%, 94.5%); I 2 =81%, P <0.01. Abbreviation: CI, confidence interval.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Improvements in bowel movement regularity with powered exoskeleton training. Notes: Data represent the proportion of subjects who reported improvements in bowel movement regularity with exoskeleton training. Fixed effects estimates: 57.7% (95% CI: 37.3%, 76.3%); random effects estimates: 60.9% (95% CI: 19.5%, 94.5%); I 2 =81%, P <0.01. Abbreviation: CI, confidence interval.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Incidence of falls with a powered exoskeleton. Notes: Data represent the proportion of subjects who experienced a fall at any point during the training period. Fixed effects estimates: 4.3% (95% CI: 1.1%, 10.8%); random effects estimates: 4.4% (95% CI: 1.0%, 10.0%); I 2 =11%, P =0.34. Abbreviation: CI, confidence interval.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Incidence of falls with a powered exoskeleton. Notes: Data represent the proportion of subjects who experienced a fall at any point during the training period. Fixed effects estimates: 4.3% (95% CI: 1.1%, 10.8%); random effects estimates: 4.4% (95% CI: 1.0%, 10.0%); I 2 =11%, P =0.34. Abbreviation: CI, confidence interval.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques:

Incidence of fractures with a powered exoskeleton. Notes: Data represent the proportion of subjects who experienced a bone fracture at any point during the training period. Fixed effects estimates: 3.4% (95% CI: 0.7%, 9.5%); random effects estimates: 3.4% (95% CI: 0.7%, 8.1%); I 2 =0%, P =0.98. Abbreviation: CI, confidence interval.

Journal: Medical Devices (Auckland, N.Z.)

Article Title: Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis

doi: 10.2147/MDER.S103102

Figure Lengend Snippet: Incidence of fractures with a powered exoskeleton. Notes: Data represent the proportion of subjects who experienced a bone fracture at any point during the training period. Fixed effects estimates: 3.4% (95% CI: 0.7%, 9.5%); random effects estimates: 3.4% (95% CI: 0.7%, 8.1%); I 2 =0%, P =0.98. Abbreviation: CI, confidence interval.

Article Snippet: The ReWalkTM (ReWalk Robotics, Inc., Marlborough, MA, US) powered exoskeleton was evaluated in eight studies, – , , – Ekso ® (Ekso Bionics, Richmond, CA, US) in three studies, – Indego TM (Parker Hannifin Corp., Cleveland, OH, US) in two studies, , and an unspecified exoskeleton in one study.

Techniques: